Introduction
A diagnosis of spinal muscular atrophy (SMA) can be life-changing for both patients and their families. Because SMA is a rare genetic neuromuscular disorder that affects muscle strength and movement, early access to disease-modifying treatment can play an important role in long-term care and preserving motor function.
Evrysdi is a prescription medication approved to treat spinal muscular atrophy in pediatric and adult patients with genetically confirmed disease. Rather than simply managing symptoms, Evrysdi targets the underlying genetic cause of SMA by helping the body produce more survival motor neuron (SMN) protein, which is essential for healthy motor neurons.
As a specialty medication used for a rare disease, Evrysdi can be expensive without adequate insurance coverage or financial assistance. Many patients and caregivers researching the Evrysdi patient assistance program are looking for ways to reduce out-of-pocket costs while maintaining access to treatment.
Prescription Hope offers access to affordable medications through patient assistance programs.
What Is the Evrysdi Patient Assistance Program?
Understanding Evrysdi Prescription Assistance
Patients looking for help paying for Evrysdi may benefit from the Evrysdi Patient Assistance Program.
Unfortunately, some brand-name medications are too expensive for many Americans to afford when they must pay retail costs for their medications.
Pharmaceutical manufacturers understand the financial burden some Americans carry and offer a useful solution: patient assistance programs.
Qualified patients receive access to affordable brand-name medication at low to no cost.
However, patient assistance programs often also come with a complex application process. Many patients struggle navigating the entire process, with some giving up and going without their medication.
Prescription Hope is dedicated to providing a solution.
How Expert Advocates Help Make Evrysdi More Affordable
Personalized Medication Assistance
Prescription Hope offers medication advocate support to qualified patients applying for programs such as the Evrysdi Patient Assistance Program.
Our patient support services offered by our team of patient advocates include form completion, document and signature collection, healthcare provider and manufacturer communication, and management of any issues that might arise during the application process.
For 20 years, Prescription Hope has used their expertise in the patient assistance program space to advocate on behalf of their patients.
Ongoing Patient Support
Not only do we offer Evrysdi application help, but we also provide continued specialty medication support.
Our team of patient advocates provides long-term medication assistance, managing administrative tasks, including refill scheduling, form and documentation updates, important information changes, yearly renewals, active program monitoring, and issue resolution.
Navigating Rare Disease Treatment Costs
Unfortunately, many brand-name specialty medications are too expensive when Americans must pay out of pocket. Because of this, patients routinely search for things like Evrysdi cost assistance or rare disease medication assistance.
Prescription Hope provides qualified patients all of their services for a simple $70.00 per month, per medication. This monthly rate not only covers all application and management services, but medication costs as well.
Plus, if a patient does not qualify for their intended program, then our team works to find a solution. Other options include: substitute medications, discount cards, coupons, or more.
And if we can’t help a patient save on their monthly medication costs, then they pay nothing!
Evrysdi Patient Assistance Eligibility
General Eligibility Requirements
Wondering who qualifies for Evrysdi assistance?
Each manufacturer sets criteria for their qualification process. Some of the general categories include:
Income: Income threshold is used as an important qualification standard. Each program differs in their income threshold.
Insurance: Similarly, insurance coverage status is also an important qualification standard. Some programs allow for limited insurance coverage, while others require complete lack of coverage to qualify.
Prescription: All programs maintain that a patient must have a valid prescription for the brand-name medication they wish to qualify for.
U.S. Residency: All qualified applicants must be a legal U.S. resident.
Simple Enrollment With Expert Support
Getting Started With Enrollment
Wanting to get started with your patient assistance registration? Looking into prescription support services?
Here are 6 simple steps to begin your medication assistance enrollment with Prescription Hope:
- Submit Information: The Prescription Hope enrollment form only takes a few minutes to complete.
- Advocate Contact: Within 1-2 business days, a patient advocate will contact patients who submitted enrollment forms.
- Document Collection: After prequalification, our team will collect important documents for the application packet.
- Provider Coordination: Prescription Hope will also communicate with your healthcare providers to secure necessary signatures.
- Program Submission: Once we complete your application, we submit all necessary materials to the manufacturer and continue to coordinate with them throughout the processing stage.
- Medication Delivery: Patients who receive approval receive their medication directly from the manufacturer. All medication ships from the manufacturer to your door or doctor’s office. Typically, initial shipments arrive within 2 weeks.
Prescription Hope is not a pharmacy or manufacturer and therefore does not handle medications at any time.
Understanding Evrysdi
How Evrysdi Works
Evrysdi is a survival motor neuron 2 (SMN2) splicing modifier that helps increase the body’s production of survival motor neuron (SMN) protein. People with spinal muscular atrophy have mutations in the SMN1 gene, resulting in insufficient amounts of SMN protein, which is essential for the health and function of motor neurons.
Evrysdi modifies how the SMN2 gene is processed so it produces more functional SMN protein. Increasing SMN protein throughout the body helps support the survival of motor neurons responsible for muscle movement and may slow the progression of spinal muscular atrophy.
By addressing the underlying genetic cause of SMA rather than only treating symptoms, Evrysdi is considered a disease-modifying therapy. Treatment is generally continued long-term to help maintain SMN protein production and support ongoing motor neuron function.
What Conditions Does Evrysdi Treat?
Evrysdi is FDA-approved for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients with genetically confirmed disease.
Spinal muscular atrophy is a rare inherited neuromuscular disorder that causes progressive loss of motor neurons, leading to muscle weakness, reduced mobility, and difficulty performing everyday activities. The severity of SMA varies depending on the individual, with some patients experiencing symptoms during infancy while others develop them later in childhood or adulthood.
Because Evrysdi is approved across a broad range of ages and disease types, healthcare providers may prescribe it as part of a long-term treatment plan designed to help preserve motor function and slow disease progression.
Benefits of Treatment
Evrysdi is designed to increase production of functional SMN protein throughout the body, helping support motor neuron health in people with spinal muscular atrophy. By addressing the underlying genetic cause of SMA, treatment may help slow disease progression while improving or maintaining motor function.
Potential benefits of Evrysdi include preserving muscle strength, supporting developmental milestones in infants and young children, improving mobility and daily functioning, and providing a convenient once-daily oral treatment that can be taken at home. The availability of both an oral solution and a 5 mg tablet for eligible patients offers flexibility for long-term treatment.
Treatment outcomes vary among individuals. Early diagnosis and treatment generally provide the greatest opportunity to preserve motor neuron function, and healthcare providers routinely monitor treatment response, motor development, and overall progress throughout therapy.
Important Safety Information and Side Effects
Evrysdi does not carry an FDA Boxed Warning.
The most commonly reported side effects include fever, diarrhea, rash, and headache. In infants and young children, additional common side effects include upper respiratory tract infections, lower respiratory tract infections such as pneumonia, constipation, vomiting, and cough. Most side effects are mild to moderate, but patients should contact their healthcare provider if symptoms become severe or persistent.
Based on findings from animal studies, Evrysdi may cause fetal harm if taken during pregnancy. Patients who can become pregnant should discuss pregnancy planning with their healthcare provider, undergo pregnancy testing when appropriate, and use effective contraception during treatment and for at least one month after the final dose. Patients who become pregnant while taking Evrysdi should notify their healthcare provider promptly.
Animal studies also suggest that Evrysdi may impair male fertility. Patients who may wish to father children in the future should discuss fertility preservation options with their healthcare provider before starting treatment.
It is unknown whether risdiplam passes into human breast milk. Patients should discuss breastfeeding plans with their healthcare provider before beginning treatment.
Evrysdi may increase blood levels of medications that are eliminated through multidrug and toxin extrusion (MATE) transporters, including certain medications such as metformin. Patients should tell their healthcare provider about all prescription medications, over-the-counter medications, vitamins, and herbal supplements they take, as additional monitoring or dose adjustments may be necessary.
Evrysdi is taken once daily and may be taken with or without food. It is available as an oral solution and, for eligible patients, a 5 mg oral tablet. The oral solution may also be administered through a feeding tube when appropriate. Dosing is individualized based on age and body weight, and patients should carefully follow storage, preparation, and administration instructions provided with the medication.
Healthcare providers typically monitor motor function, developmental milestones in pediatric patients, treatment response, adverse effects, and body weight throughout treatment, as weight changes may require dosage adjustments.
Access to Multiple Medications
Support Beyond Evrysdi
Patients needing rare disease medication support often also require other specialty medications. This has patients routinely looking for multiple medication assistance programs to help cover their brand-name medications included in their treatment protocol.
Prescription Hope offers access to hundreds of brand-name medications. This means we can help you access as many medications as you qualify for on our list.
And our service fee remains a simple $70.00 per month, per medication.
Why Choose Prescription Hope for Evrysdi Assistance
Patient-Focused Medication Support
As medication access specialists, Prescription Hope offers patient-centered assistance for Americans across the nation. For two decades, we have provided compassionate advocacy and prescription affordability support.
Simplified Access to Specialty Therapies
Our treatment affordability solutions mean people looking for things like spinal muscular atrophy medication access and qualify can get it for a simple $70.00 per month, per medication.
Ongoing Prescription Assistance
Our long-term medication support not only offers affordable Evrysdi access, but provides patients with continued SMA treatment support for as long as they are with us. We handle refill scheduling, document updates, form changes, issue resolution, yearly renewals, and more.
If you need access to the Evrysdi Patient Assistance Program, then be sure to enroll with Prescription Hope today!